We used a specific method to measure conjugated bilirubin levels in patient
s with acute liver diseases to examine its clinical usefulness. Conjugated
and total bilirubin levels were measured in 102 samples obtained from six p
atients with acute liver diseases (three with fulminant hepatic failure, on
e with acute severe hepatitis and two with acute hepatitis: see text for cr
iteria). Total and conjugated bilirubin levels were measured with Iatro T (
total)-Bil and D (direct)-Bil kits (Iatron Laboratories Tokyo, Japan) and w
ith conventional Nescauto T(total)-Bil and D(direct)-Bil VE kits (Nippor Sh
oji, Osaka, Japan). The Iatro D-Bil kit measures conjugated bilirubin corre
ctly, while the Nescauto D-Bil VE kit measures some nonconjugated bilirubin
and delta bilirubin as well as conjugated bilirubin. Total bilirubin level
s determined by the two methods showed good correlation. The conjugated bil
irubin level measured with the Iatro D-Bil kit was strongly correlated with
the direct bilirubin level measured with the Nescauto D-Bil VE kit, but th
ere was no correlation between the conjugated-to-total bilirubin ratio and
the direct-to-total bilirubin ratio. When we examined the changes in biliru
bin levels in our patients with respect to outcome. wee found that the two
patients in whom the ratio of conjugated-to-total bilirubin exceeded 0.3 di
ed, while all four patients in whom the ratio remained below 0.3 survived.
The ratio of direct-to-total bilirubin was unrelated to outcome. The conjug
ated bilirubin level measured with the Iatro kits was therefore considered
useful for the diagnosis and follow-up of acute liver diseases.